Be Clinical Raises Rs. 21 Crore to Build a Science-Led Skincare Brand for Indian Consumers

Be Clinical has raised Rs. 21 crore in a seed extension round led by Sauce, giving the young skincare brand fresh capital to grow its clinical skincare business in India.

The round also saw participation from existing investor V3 Ventures and several angel investors, including Mokobara founders Sangeet Agrawal and Navin Parwal, Reckitt executive Arjun Purkayastha and Shaunak Chirayu Amin.

This funding matters because India’s skincare market is changing quickly. Customers are no longer buying products only because of fragrance, packaging or celebrity ads. Many now want products that are tested, ingredient-led and made for real skin concerns such as ageing, dryness, fine lines, dullness, pigmentation and skin barrier damage.

What Be Clinical does

Be Clinical is a D2C skincare brand focused on science-backed and clinically tested skincare products. Its main focus is ageing-related skin concerns for Indian consumers.

The brand was founded by Hemangi Dhir. Be Clinical was launched in 2025 after nearly two years of research and development.

Be Clinical’s products use dermatologically active ingredients. In simple words, these are ingredients used to target specific skin concerns instead of giving only a cosmetic feel. The brand says it tests products for safety and effectiveness before launching them.

Its portfolio includes products such as PlumpX Serum, FirmX Serum, Revive 10 Eye Cream and Neck Repair Cream. These products are aimed at people looking for skincare that supports firmness, hydration, under-eye care and visible ageing concerns.

Aim of the startup

Be Clinical’s aim is to make clinical skincare easier to access for Indian consumers.

Many people want effective skincare, but they often feel confused. One product says anti-ageing, another says brightening, another says repair, and many use complicated ingredient names. Be Clinical is trying to build a brand where products are more focused, tested and transparent.

The brand is also trying to address Indian skin and Indian environmental conditions. This is important because skin concerns can be affected by heat, pollution, humidity, sun exposure and lifestyle habits.

For example, someone living in Delhi may face pollution-related dullness and dryness. Someone in Mumbai may deal with humidity and clogged pores. A person in their late 20s may start noticing early fine lines or loss of firmness. Be Clinical wants to create products for these specific needs rather than offering one general cream for everyone.

Purpose of the Rs. 21 crore funding

Be Clinical will use the new funding to strengthen research and development, expand its skin, body and haircare portfolio, scale manufacturing capacity and enter new markets.

The company also plans to invest more in clinical testing and manufacturing capabilities. This is important because skincare brands need consistency. A serum or cream should perform the same way batch after batch.

In-house manufacturing can help the brand control product quality, protect its formulations and respond faster to customer needs. It also gives the company more control over ingredients, testing and production timelines.

The funding will also help Be Clinical build a larger product range. So far, its focus has been strongly around ageing solutions for skin. Going ahead, it wants to expand into body and haircare products as well.

Why clinical skincare is gaining attention

Indian consumers have become more ingredient-aware. Many buyers now read labels, search for actives, compare reviews and ask whether a product is tested.

This shift has opened space for brands that are not only marketing-led but product-led. Be Clinical is trying to use that change by focusing on clinical testing, in-house R&D and targeted formulations.

Clinical skincare does not mean a product is a medicine. It simply means the brand is trying to support its claims with testing and scientific formulation. Customers should still choose products based on their skin type and consult a dermatologist for serious skin problems.

Growth and traction

Be Clinical claims to have delivered 1.2 lakh orders since launch, according to report by Inc42. The company also says it has recorded a healthy share of repeat purchases.

Repeat purchase is important in skincare. If customers buy again, it usually means the product experience was good enough for them to return. In beauty and personal care, repeat buying can become a strong sign of trust.

Be Clinical sells mainly through its own website. Its products are also available on ecommerce platforms such as Amazon and Flipkart.

Previous funding

Before this Rs. 21 crore seed extension round, Be Clinical had raised Rs. 6 crore in seed funding led by V3 Ventures, with participation from Titan Capital.

Earlier, it had also raised Rs. 2 crore from Titan Capital and Aditya Agarwal, founder of P-TAL.

This means investor interest in the brand has grown across multiple rounds. The latest Sauce-led round gives Be Clinical more capital to scale its science-first skincare model.

Competitors of Be Clinical

Be Clinical operates in a crowded skincare market. Its competitors include Indian D2C skincare brands such as Dr. Sheth’s, Pilgrim, Innovist, Minimalist, The Derma Co, Foxtale, Plum and Mamaearth.

It also competes with global skincare brands such as Clinique, Neutrogena and Cetaphil.

Be Clinical’s main difference is its focus on ageing solutions, clinical testing and in-house manufacturing. But the brand will need to keep proving its quality because skincare buyers are becoming more careful and better informed.

What Be Clinical needs to get right

The biggest challenge for Be Clinical will be trust.

Skincare is personal. A product that works for one person may not work for another. So the brand must communicate clearly, avoid exaggerated promises and educate users properly.

It also needs to keep pricing sensible. Clinical skincare can easily become expensive, but India is a price-sensitive market. If Be Clinical can balance quality and affordability, it can reach a much larger audience.

The company must also manage product safety carefully as it expands into more categories. Bodycare and haircare are large opportunities, but each needs separate testing, formulation and customer education.

Conclusion with key takeaways

Be Clinical’s Rs. 21 crore seed extension round shows that investors are still interested in focused, science-led D2C beauty brands. The brand is not trying to sell skincare only through trends. It is building around clinical testing, active ingredients and ageing-related concerns for Indian consumers.

With Sauce leading the round and V3 Ventures continuing its support, Be Clinical now has more room to expand R&D, manufacturing, product categories and market reach.

Key takeaways –

• Be Clinical has raised Rs. 21 crore in a seed extension round.
• The round was led by Sauce.
• V3 Ventures and several angel investors also participated.
• The brand was founded by Hemangi Dhir and launched in 2025 after two years of R&D.
• Be Clinical focuses on clinically tested skincare for ageing-related concerns.
• The funding will support R&D, manufacturing, new products, team growth and expansion into new markets.